Spero Therapeutics Inc (SPRO)
1.175
-0.02
(-1.26%)
USD |
NASDAQ |
Nov 22, 16:00
1.175
0.00 (0.00%)
After-Hours: 20:00
Spero Therapeutics Total Liabilities (Quarterly): 69.65M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 69.65M |
| June 30, 2024 | 69.38M |
| March 31, 2024 | 71.45M |
| December 31, 2023 | 75.50M |
| September 30, 2023 | 53.40M |
| June 30, 2023 | 44.10M |
| March 31, 2023 | 47.71M |
| December 31, 2022 | 48.87M |
| September 30, 2022 | 31.99M |
| June 30, 2022 | 27.70M |
| March 31, 2022 | 83.36M |
| December 31, 2021 | 82.78M |
| September 30, 2021 | 32.80M |
| June 30, 2021 | 29.34M |
| March 31, 2021 | 24.59M |
| December 31, 2020 | 21.41M |
| Date | Value |
|---|---|
| September 30, 2020 | 24.25M |
| June 30, 2020 | 23.83M |
| March 31, 2020 | 27.47M |
| December 31, 2019 | 31.53M |
| September 30, 2019 | 19.48M |
| June 30, 2019 | 12.82M |
| March 31, 2019 | 11.32M |
| December 31, 2018 | 13.15M |
| September 30, 2018 | 10.57M |
| June 30, 2018 | 6.924M |
| March 31, 2018 | 6.161M |
| December 31, 2017 | 8.522M |
| September 30, 2017 | 7.273M |
| June 30, 2017 | 6.844M |
| December 31, 2016 | 7.411M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
21.41M
Minimum
Dec 2020
83.36M
Maximum
Mar 2022
46.06M
Average
38.45M
Median
Total Liabilities (Quarterly) Benchmarks
| CytomX Therapeutics Inc | 162.43M |
| Johnson & Johnson | 108.13B |
| Arbutus Biopharma Corp | 33.55M |
| Equillium Inc | 11.28M |
| NovaBay Pharmaceuticals Inc | 2.805M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 135.16M |
| Shareholders Equity (Quarterly) | 65.51M |
| Current Ratio | 2.681 |